Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring.

Clinical chemistry - 1 Nov 2021

Hallermayr Ariane, Benet-Pagès Anna, Steinke-Lange Verena, Mansmann Ulrich, Rentsch Markus, Holinski-Feder Elke, Pickl Julia M A

Abstract excerpt

BACKGROUND: Analysis of circulating tumor DNA (ctDNA) in plasma is a powerful approach to guide decisions in personalized cancer treatment. Given the low concentration of ctDNA in plasma, highly sensitive methods are required to reliably identify clinically relevant variants. METHODS: We evaluated the suitability of 5 droplet digital PCR (ddPCR) assays targeting KRAS, BRAF, and EGFR variants for ctDNA analysis in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasm, Residual

Share to Polymerase Chain Reaction

Source

Identifiers

PMID: 34392332
DOI: 10.1093/clinchem/hvab124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring.PMID 34392332Read ↗

A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)Semantic proximity Read ↗

Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA.Semantic proximity Read ↗

Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral HeterogeneitySemantic proximity Read ↗

Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.Semantic proximity Read ↗

Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.Semantic proximity Read ↗

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.Semantic proximity Read ↗

Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.Semantic proximity Read ↗

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.Semantic proximity Read ↗

MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reactionSemantic proximity Read ↗

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCRSemantic proximity Read ↗

Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.